



2021 APSARD Virtual Conference January 15-17, 2021 **PROGRAM BOOK**


ADHD in the Era of COVID: Maintaining Focus

APSARD



The American Professional Society
of ADHD and Related Disorders





After the highs and lows of 2020 Look forward to days of low peak-to-trough variability in 2021

Attend the Symposium to learn how JORNAY PM can provide predictability in an ADHD world.

Ironshore Symposium:
JORNAY PM: A paradigm shift in ADHD
therapy by targeting colonic absorption
Friday, January 15, 2021 at 9:45 AM EST
and continue the focus in the Ironshore Virtual Booth.



INDICATION

JORNAY PM is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including JORNAY PM, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

[Click here to see accompanying Full Prescribing Information, including Boxed Warning.](#)



A LETTER FROM OUR 2021 PROGRAM CHAIR

Dear Colleagues,

On behalf of the APSARD Annual Meeting Program Committee, we are delighted to welcome you to the 2021 APSARD Annual Meeting. No other meeting has such a rich blend of cutting-edge research and up-to date clinical knowledge as APSARD; and this year's meeting promises to be even more ambitious and filled with interesting content.

Owing to the COVID pandemic, the meeting will be in an all-virtual format. This will not be a standard Zoom meeting like we've all been enamored with this year. We have a custom-built virtual platform that will look and feel as close to a convention hall as possible. In addition to the sessions, there will be rooms with activities to connect with others, you can chat people individually, view and chat with poster presenters, and there will always be someone available to assist if you have technical difficulties or questions. Also, all post-conference content will be available for up to 60 days after the conference, so if you cannot make one session, you will not miss a thing. We are of course sorry that we are unable to meet face to face, but we have done everything we can to not let the virus slow us down and take full advantage of the on-line format we will be using. We have strived to preserve all that is educational about our person meetings - including robust scientific sessions with both a clinical and academic focus, poster sessions, meetings with experts in the field and networking with APSARD leadership and colleagues. We have vastly expanded the number of presentations this year, with a particular focus on the impact of COVID on our patients and on the field and have also incorporated an enhanced focus on diversity. In all, there are 30 clinical/scientific sessions, 65 posters, and two industry-funded symposia.

The meeting content includes presentations covering neuroimaging, parenting, suicide, multicultural factors, and substance abuse, as well the latest on psychosocial and psychopharmacological treatments. We examine and critique recent guidelines for clinical care in ADHD, with a strong international prescriptive. The latter is greatly enhanced by the on-line format – the roster of presenters includes leading authorities on ADHD from 23 countries and 5 (check this) continents! In addition, there will be opportunity to personally network with senior APSARD leaders to discuss clinical and research issues.

This year, we especially wanted to reach out to trainees and others who are relatively new to our field. To support this agenda, we have added a pre-meeting institute on ADHD across the lifespan. This will be followed by sessions during the meeting highlighting information from the international consensus statement on ADHD, which was recently produced by the World Federation on ADHD.

The annual APSARD meeting is a major crossroads for experienced clinicians and prominent researchers in the area of ADHD and its related disorders. The information in the over 30 sessions will impact clinical your practice and research program. I look forward to seeing you in January!

Yours Sincerely,

Steven Pliszka, M.D.
APSARD 2021 Program Chair

www.apsard.org

A LETTER FROM OUR PRESIDENT



Dear APSARD Colleagues:

It is my pleasure to welcome you to the 2021 Meeting of the American Professional Society of ADHD and Related Disorders! APSARD is the premier, multidisciplinary, US-based organization, devoted to the advancement of both the science and clinical practices benefitting individuals with ADHD and comorbid disorders across the lifecycle. This year's program is enriched with state-of-the-art plenaries and symposia addressing key issues affecting the field. As always, we will also have a wide range of posters that cover emerging research in ADHD. Our virtual platform will offer the opportunity to interact with the presenters and networking opportunities with prominent investigators, clinicians, and colleagues from around the globe who all come to APSARD.


This year, we have undertaken several new initiatives. We have extended the length of the meeting, accepted symposia from the field (while still commissioning several others, as well), added industry-sponsored sessions, and developed programming for trainees and/or newcomers to the field. Most importantly, we have highlighted topical issues related to equality and diversity, and of course, the Covid-19 pandemic. Of note, although there are many parallel sessions each day, there is ample time to listen to all of them – as all the sessions will be recorded and available for viewing on-line for 60 days following the conclusion of the meeting. Naturally, we mourn being able to meet “live” and network with one another as is our usual practice. However, we have embraced the opportunities offered by the on-line format, offering what we hope is the next best thing in terms of interaction among colleagues. Most importantly, we are excited by the opportunity to engage a diverse and highly accomplished group of international presenters via the on-line format, and to reach many new attendees from around the world.

Despite increasing awareness of ADHD in all age groups, huge educational gaps remain among primary and specialty care providers, and there is limited access to evidence-based knowledge, especially in preschool children, adults and older adults. Controversy, biases and misinformation continue to handicap our field. We need your help in broadening the reach of APSARD and achieving our scientific and educational goals. Please introduce yourself to any board member or officer if you have suggestions or feedback and ask about volunteering for APSARD committees. We also hope you will participate in our educational activities throughout the year, refer colleagues for membership, and become more involved in this diverse and robust organization.

I know you will enjoy the meeting and interacting with your APSARD colleagues.

With warm regards,

Jeffrey Newcorn, MD
APSARD President



2020 - 2021 BOARD OF DIRECTORS

Jeffrey Newcorn, M.D.– President
 Ann Childress, M.D.– President Elect
 Joseph Biederman, M.D.– Past President
 David Goodman, M.D. – Secretary
 Tanya Froehlich, M.D.– Treasurer
 Maria Acosta, M.D.
 Lenard Adler, M.D.
 Kevin Antshel, Ph.D.
 Anne Arnett, PH.D.
 Jacob Behrens, M.D.
 Lawrence Brown, M.D.
 Thomas Brown, Ph.D.
 Betsy Busch, M.D., FAAP
 Sam Goldstein, Ph.D.

John Heiligenstein, M.D.
 Beth Krone, Ph.D.
 Frances Levin, M.D.
 Greg Mattingly, M.D.
 Keith McBurnett, Ph.D.
 Brooke Molina, Ph.D.
 Andrew Nierenberg, M.D.
 Joel Nigg, Ph.D.
 Anthony Rostain, M.D., MA
 Mary Solanto, Ph.D.
 Mark Stein, Ph.D.
 Craig Surman, M.D.
 Roberta Waite, Ph.D.

2021 PROGRAM COMMITTEE MEMBERS

Steven Pliszka, M.D.
 University of Texas San Antonio, Chair

Joseph Biederman, M.D.
 Massachusetts General Hospital

Ann Childress, M.D.
 Center for Psychiatry and Behavioral Medicine

Margaret Weiss, M.D., Ph.D. FRCP(C)
 Cambridge Health Alliance

Anne Arnett, Ph.D
 University of Washington

Frances Levin, M.D.
 Columbia University Medical Center

Brooke Molina, Ph.D
 University of Pittsburgh

Jeffrey Newcorn, M.D.
 Icahn School of Medicine at Mount Sinai

Roberta Waite, EdD, PMHCNS, FAAN, ANEF
 Drexel University

Russell Schachar, M.D.
 University of Toronto

Martin Katzman, B.Sc.,FRCP(C),M.D.
 START Clinic for Mood and Anxiety Disorders

APSARD Board Recognition

APSARD would not be successful without the hard work of our board members. We are grateful for their time, dedication and passion for better the field of ADHD and related disorders.

To our new board members, welcome.

To our re-elected board members, we are grateful for your continued service. To our departing board members, thank you for your commitment to APSARD, we look forward to growing your legacy.

THANK YOU TO OUR DEPARTING BOARD MEMBERS:

LAWRENCE BROWN, MD
BETSY BUSCH, MD, FAAP
JOHN HEILIGENSTEING, MD
ANTHONY ROSTAIN, MD, MA
CRAIG SURMAN, MD

RE-ELECTED BOARD MEMBERS:

BETH KRONE, PHD
BROOKE MOLINA, PHD
KAREN SEYMOUR, PHD
TANYA FROHLICH, MD
MARK STEIN, PHD

NEW BOARD MEMBERS:

MARK BERTIN, MD
J FAYE DIXON, PHD
MARTIN KATZMAN, B.Sc., FRCP®, MD

2021 CONFERENCE SUPPORT

APSARD would like to acknowledge the generosity of the following companies whose unrestricted educational grants have contributed to the overall quality of the meeting:

Supernus Pharmaceuticals

2021 SPONSORS & EXHIBITORS

PLATINUM SPONSORS



BRONZE SPONSOR



AWARD SPONSOR



CONFERENCE SPONSOR



EXHIBITORS



CONTINUING EDUCATION CREDITS

2021 Meeting Evaluation Information

All meeting attendees are urged to complete an evaluation of the meeting. Attendees who are requesting CE credits for the meeting are required to complete the evaluation. This form is available online only. At the conclusion of the meeting, you may complete the evaluation online at www.apsard.org (click the Annual Meeting tab). All evaluations must be completed by **April 1, 2021**. Your certificate will be emailed upon completion, please check your junk mail if you do not receive it.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Professional Society of ADHD & Related Disorders. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians and Nurses

Credit Designation Statement – Live Content – Amedco LLC designates the live activity portion for a maximum of 21.75 AMA PRA Category 1 Credits™ for physicians and 21.75 ANCC contact hours for nurses.

Credit Designation Statement – Enduring/Recorded Content – Amedco LLC designates the enduring material activity portion for a maximum of 39.50 AMA PRA Category 1 Credits™ for physicians and 43.75 ANCC contact hours for nurses.

Learners should claim only the credit commensurate with the extent of their participation in the activities. The 21.75 live hours cannot also be claimed as enduring hours.

Psychologists

Amedco LLC designates the live activity for a maximum of 21.00 psychologist contact hours and the enduring/recorded content for a maximum of 43.0 hours. The 21.00 live hours cannot also be claimed as enduring hours.

Social Workers

As a Jointly Accredited Organization, Amedco is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Amedco maintains responsibility for this course. Social workers completing this course receive 21.00 GENERAL continuing education credits for the live content and 43.0 GENERAL continuing education credits for the enduring/recorded content. The 21.00 live hours cannot also be claimed as enduring hours.

Objectives – After attending this program, you should be able to:

1. Discuss new findings regarding the longitudinal course of ADHD and its impact on the functional status of individuals with ADHD.
2. Explain how to apply interdisciplinary approaches to a variety of psychosocial treatments for individuals with ADHD.
3. Name the basic principles of brain connectivity and define its role in ADHD/related disorders.





Congratulations!

2021 Tris Research Award Winners

You can view the Tris Research Award winners' posters in the [e-Poster gallery](#).
Be sure and leave comments or notes of congratulations in the discussion forum.

- 1. Repetitive Mild Traumatic Brain Injury in a Perinatal Nicotine Exposure Mouse Model of ADHD**
ZHANG, LIN; Biomedical Sciences, Florida State University College of Medicine
- 2. Kappa opioid receptor antagonists show therapeutic potential in preclinical model of Autism Spectrum Disorder**
McCarthy, Deirdre; Center for Brain Repair, Florida State University College of Medicine
- 3. Emotion Dysregulation in Adult ADHD: Reactive Aggression Predicts Hyperactivation of the Limbic System**
Jakobi, Babette; Radboud University Nijmegen, Donders Centre for Cognitive Neuroimaging

